Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2026-01-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
内幕信息知情人登记管理制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal management system for insider information registration and management for a company, including definitions, scope, responsibilities, and procedures related to insider information. It references laws and regulations related to securities and insider trading, outlines the roles of board members and management, and describes confidentiality and reporting obligations. There is no financial data, earnings information, or report publication announcement. It is not a report of financial results, audit, or legal proceedings. It is a regulatory compliance document related to insider information management and internal governance. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and regulatory document that does not fit other specific categories.
2026-01-13 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the company's policies and procedures for managing investor relations, including communication with investors, compliance with laws and regulations, and internal responsibilities. The content is focused on governance and management of investor relations rather than financial results, audit, or specific event announcements. It does not contain financial statements, earnings data, or voting results. It is a governance-related document detailing internal rules and practices for investor relations management. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5690 characters) and detailed procedural content support this classification with high confidence.
2026-01-13 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2026 first extraordinary general meeting (临时股东会) of Luoxin Pharmaceutical Group Co., Ltd. It includes information about meeting time, voting procedures, proposal details, and proxy forms. The content focuses on the announcement and procedural details for a shareholders' meeting, including election of board members and amendments to company rules. There is no financial data, earnings, or audit information presented. The document is not a report itself but a formal meeting notice and related materials for shareholder voting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the results or solicitation materials, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length (5663 characters) and detailed voting instructions support this classification.
2026-01-13 Chinese
第五届董事会第三十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 36th meeting of the 5th Board of Directors of Luoxin Pharmaceutical Group Co., Ltd. It includes nominations for the new board, amendments to company bylaws and various internal management systems, and plans for a forthcoming shareholders meeting. The content focuses on board decisions, nominations, and governance-related matters. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement of board meeting resolutions. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (8717 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2026-01-13 Chinese
股东会议事规则
Governance Information Classification · 100% confidence The document is titled as "股东会议事规则" which translates to "Rules of Procedure for Shareholders' Meetings" for 罗欣药业集团股份有限公司. The content extensively details the procedures, rules, and regulations governing the convening, notification, proposal submission, voting, and resolutions of shareholders' meetings. It includes references to legal frameworks, voting rights, meeting conduct, and other governance-related matters. There is no financial data, earnings information, or report publication announcement. The document is a governance-related procedural manual rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2026-01-13 Chinese
董事会议事规则
Governance Information Classification · 95% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of 罗欣药业集团股份有限公司. It details the structure, duties, responsibilities, meeting procedures, and governance rules of the company's board of directors. There is no financial data, audit information, or report content. It is a governance document outlining internal rules and board operations. This matches the description of Governance Information (CGR). The document length is over 11,000 characters, indicating it is a full document, not a brief announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2026-01-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.